INC Research (NASDAQ: SYNH) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare INC Research to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, institutional ownership and earnings.
Insider & Institutional Ownership
99.5% of INC Research shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 0.2% of INC Research shares are owned by insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
INC Research has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, INC Research’s rivals have a beta of 1.53, indicating that their average share price is 53% more volatile than the S&P 500.
Valuation & Earnings
This table compares INC Research and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|INC Research||$1.61 billion||$112.63 million||-70.52|
|INC Research Competitors||$217.40 million||-$39.40 million||-48.27|
INC Research has higher revenue and earnings than its rivals. INC Research is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares INC Research and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|INC Research Competitors||-4,062.74%||-476.46%||-42.10%|
This is a breakdown of current ratings and recommmendations for INC Research and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|INC Research Competitors||678||2573||6785||136||2.63|
INC Research presently has a consensus price target of $49.88, indicating a potential upside of 21.94%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.48%. Given INC Research’s higher probable upside, equities analysts plainly believe INC Research is more favorable than its rivals.
INC Research beats its rivals on 7 of the 13 factors compared.
About INC Research
Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with MarketBeat.com's FREE daily email newsletter.